ESR1 and melanoma: All of the synthesized compounds (7a–f) were studied to test their anticancer activity toward the estrogen receptor-positive (ER+) MCF-7 and the triple-negative MDA-MB-231 breast cancer cells (ER-, PR- and HER-2/Neu not overexpressed) and A2058 melanoma cells.